Search
Create
Log in
Sign up
Log in
Sign up
New Drugs
STUDY
Flashcards
Learn
Write
Spell
Test
PLAY
Match
Gravity
Terms in this set (45)
Plan B two pill
brand no longer marketed- generic
17+
7% use it right
Plan B one step
$50
no age restrictions
Teva has 3 year exclusivity
Obesity and EC
3x greater risk of obese women getting pregnant with morning after pill
165lbx + may want to consider copper IUD
Lidopatch
doesn't actually exist
lidoderm patch claims it may be confusing since it's not the same product
nexafed
polymer matrix to prevent extraction of methamphetamine
still behind counter
abreva conceal
has no medication
just covers
oxytrol OTC
overactive blader in WOMEN 18+
new patch every 4 days
oxytrol otc indications
urinating 8x or more per day
urgent need to urinate
not able to control the urge
oxytrol OTC effectiveness
reduced frequency by one episode a day
asthmanefrin (racepinephrine)
4yo and up
alternative to primatene mist
no CFC or preservatives
asthmanefrin counseling
don't touch with mouth
clean each night with vinegar for 3 minutes
no more than 2d/w; wo MD
go to ER if SOB after 20 minutes
What drugs just made the RX OTC switch?
nexium (esomeprazole)
nasacort AQ (triamcinolone acetonide)
nasacort AQ
2 yo +
nasal allergy sx
hydrocodone reclassification
Schedule III but petition out to make it CII
Tylenol combo products
recommendation to no longer have products over 325mg
zohydro
ER hydrocodone
severe pain, ATC long term opiate needs
not for PRN
Zohydro safety
working on a tamper proof system - right now you can easily get yourself dead from it
ER/LA opioids labeling
BBW - neonatal opioid withdrawal syndrome
indicated for pain severe enough to require daily, ATC longer term opioid tx for which alternative therapies are inadequate
evzio
naloxone HCl injection
opioid OD
0.4mg/mL prefilled auto injector
AHA guidelines 4 groups of pts
CV disease
LDL 190+
DM2 and between 40-75 yo
10 year CVD risk 7.5% or higher and 40-75 yo
New AHA guidelines effect
31million new people on statins
guidelines are new
JNC 8
high blood pressure
2014
same staging as JNC 7
JNC8 BP goals
18-59 including DM and CKD <140/90
>60 yo <140/90
>60 <150/90 - relaxed and controversial
JNC 8 recommendations
BB no longer recommended for BP control
split panel on 2 drug combo
AFib new significant recommendations
increased use of radio freq ablation in tx of nonvalvular AF
novel oral anticoagulants
diminished role of ASA
endorse CHA2DS2-VASc
CHADS-VASC
added vascular dx, age, sex
gave age an extra point
more predictive - esp in older women
Pradaxa
dabigatran
lower risk of clot related strokes, bleeding in brain, and death than warfarin
inc risk of major GI bleed
MI risk similar
Farixga
dapagliflozin 5 & 10 mg
CI in severe renal impairment <60
lowers A1C by 0.8-0.9
Farixga MOA
SGLT2 inhibitor - reduces reabsorption of filtered glucose - lowers renal threshold for glucose - increases glucose excretion
AEs of farixga
inc LDL
female genital mycotic infections
nasopharyngitis
UTI
Avandia
rosiglitazone
non inc heart attack - poor Dunbar
REMS will be modified
Zolpidem
ambien
lower dose for the women folk
from 10mg - 5mg
from 12.5 to 6.25 ER
Diclegis
doxylamine succinate and pyridoxine HCl 10/10
morning sickness
diclegis directions
take 2 tabs in the evening on an empty stomach
may add 3rd on day 3
may add 4th on day 4 midafternoon
Diclegis cons
very expensive
try to do non pharm stuff first
Breo Ellipta
fluticasone/vilanterol
inhaled corticosteroid/LABA
COPD
Breo Ellipta counseling
1 inhalation
opening cover activates - lose dose if you close without taking it
expires 6 weeks from removal of pouch
Breo Ellipta BBW
LABA increase risk of asthma related death and should not be used as rescue therapy
Anoro Ellipta
umeclidinium LAMA and livanterol LABA
COPD
one inhalation daily
Dalvance
dalbavancin injection
acute bacterial skin and skin structure infections ABSSSI caused by Gram +
covers MRSA and MSSA
dalvance dose
two dose regimen
1000 mg IV x1 dose over 30 mins
following week 500mg IV x 1 dose infused over 30 mins
Trials for dalvance
Discover 1 and Discover 2
non inferior
dalliance class
2nd gen semi synthetic lipoglycopeptide
GAIN
generating Abx incentives NOW
passed 2012
granted priority review as QIDP
QIDP
qualified infectious disease product
;